Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck

Head and Neck

Volumn 37, Issue 2, 2015, Pages 182-187

  Thomson, David J ^a   Silva, Priyamal ^a   Denton, Kim ^a   Bonington, Suzanne ^a   Mak, Soo K ^a   Swindell, Ric ^a   Homer, Jarrod ^a   Sykes, Andrew J ^a   Lee, Lip W ^a   Yap, Beng K ^a   Slevin, Nicholas J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Adenoid cystic carcinoma; Sorafenib; Trial

Indexed keywords

SORAFENIB; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHAGIA; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HUMAN; HYPERTENSION; LIVER DYSFUNCTION; MALE; METASTASIS; MIDDLE AGED; MOOD DISORDER; NAUSEA; NEUTROPENIA; ORAL MUCOSITIS; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SALIVARY ADENOID CYSTIC CARCINOMA; SALIVARY GLAND CARCINOMA; STOMACH DISEASE; TINNITUS; VOMITING; ANALOGS AND DERIVATIVES; CARCINOMA, ADENOID CYSTIC; CLINICAL TRIAL; DISEASE COURSE; MORTALITY; SALIVARY GLAND NEOPLASMS;

ADULT; AGED; CARCINOMA, ADENOID CYSTIC; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; SALIVARY GLAND NEOPLASMS;

EID: 84921436666     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23577     Document Type: Article

References (28)

1. Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies. Oral Oncol 2006; 42:759-769.
2. Bjørndal K, Krogdahl A, Therkildsen MH, et al. Salivary gland carcinoma in Denmark 1990-2005: a national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA). Oral Oncol 2011; 47:677-682.
3. Ellington CL, Goodman M, Kono S.A., et al. Adenoid cystic carcinoma of the head and neck: incidence and survival trends based on 1973-2007 Surveillance, Epidemiology, and End Results data. Cancer 2012; 118:4444-4451.
4. Bradley PJ. Adenoid cystic carcinoma of the head and neck: a review. Curr Opin Otolaryngol Head Neck Surg 2004; 12:127-132.
5. Papaspyrou G, Hoch S, Rinaldo A., et al. Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011; 33:905-911.
6. Terhaard CH, Lubsen H, Van der Tweel I, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck 2004; 26:681-692; discussion 692-693
7. Hotte SJ, Winquist EW, Lamont E, et al. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 2005; 23:585-590.
8. Pfeffer MR, Talmi Y, Catane R., Symon Z, Yosepovitch A, Levitt M. A phase II study of imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 2007; 43:33-36.
9. Ghosal N, Mais K, Shenjere P., et al. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma. Br J Oral Maxillofac Surg 2011; 49:510-515.
10. Liu J, Shao C, Tan M.L., Mu D., Ferris RL, Ha PK. Molecular biology of adenoid cystic carcinoma. Head Neck 2012; 34:1665-1677.
11. Holst VA, Marshall CE, Moskaluk C.A., Frierson HF Jr. KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 1999; 12:956-960.
12. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 2000; 154: 107-111.
13. Zhang J, Peng B, Chen X. Expressions of nuclear factor kappaB, inducible nitric oxide synthase, and vascular endothelial growth factor in adenoid cystic carcinoma of salivary glands: correlations with the angiogenesis and clinical outcome. Clin Cancer Res 2005; 11:7334-7343.
14. Chau NG, Hotte SJ, Chen E.X., et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 2012; 23:1562-1570.
15. Wilhelm SM, Carter C, Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109.
16. Strumberg D, Richly H, Hilger R.A., et al. Phase I clinical and pharmacoki-netic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005; 23:965-972.
17. Escudier B, Eisen T, Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
18. Llovet JM, Ricci S, Mazzaferro V., et al. Sorafenib in advanced hepatocel-lular carcinoma. N Engl J Med 2008; 359:378-390.
19. Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 2009; 283:125-134.
20. Dammrich DJ, Santos ES, Raez LE. Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature. J Med Case Rep 2011; 5:483.
21. Eisenhauer EA, Therasse P, Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
22. Oken MM, Creech RH, Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-655.
23. Agulnik M, Cohen EW, Cohen R.B., et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007; 25:3978-3984.
24. Locati LD, Bossi P, Perrone F., et al. Cetuximab in recurrent and/or meta-static salivary gland carcinomas: a phase II study. Oral Oncol 2009; 45: 574-578.
25. Argiris A, Ghebremichael M, Burtness B., Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). Cancer 2011; 117:3374-3382.
26. Dal Lago L, D'Hondt V, Awada A. Selected combination therapy with sor-afenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 2008; 13:845-858.
27. Locati LD, Bossi P, Civelli E.M., et al. Sorafenib in recurrent and/or meta-static salivary gland carcinomas (RMSGCs): an investigator-initiated phase II trial (NCT01703455). J Clin Oncol 2013; 31(suppl; abstr 6020).
28. Williamson SK, Moon J, Huang C.H., et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010; 28:3330-3335.